Statins can reduce the risk of death from artery disease

Statins can reduce the risk of death from artery disease

WEDNESDAY, September 4, 2019 (HealthDay News) – People with peripheral artery disease (PAD) have a much lower risk of death if they accept cholesterol-reducing statistics as their doctor guides, new study reports.

Around 200 million people around the world suffer from PAD, a condition in which the arteries that feed blood at the feet suffer, and researchers explained.

However, patients who took their prescribed statins over a period of more than four years of follow-up activity had a 20% death rate, compared to about 34% for people who stopped taking statins or never started, researchers found t European. T

"This is an important observation which emphasizes the importance of adhering to statistics," said Dr. Robert Rosenson, director of cardiovascular disorders at Icahn Medical School at Mount Sinai in New York City.

Previous studies have shown the health benefits of stats in patients with PAD, but this new report shows that these benefits could lead to longer life, said Rosenson, who was not involved in the study.

"Clinicians must adhere to statin treatment to discuss with each contact," he said.

PAD can cause debilitating feet symptoms, including painful cramps, inhumanity and weakness in three out of 10 patients, researchers said. Other people develop grains in their feet due to poor circulation.

PAD also increases human margins for a seizure and heart attack, so cholesterol-lowering statins are recommended for all PAD patients, the researchers said.

Unfortunately, patients often do not take their statins as they are guided. Statistical statistical rates in Europe are around 57%, and in the US, they are 50% or lower, said Dr. Maja Zaric, an interventional cardiologist with Lenox Hill Hospital in New York City.

To assess the importance of statin therapy in PAD, Dr. led researchers. Jorn Dopheide from Bern University Hospital in Switzerland traced almost 700 patients between 2010 and 2017, with 50 months follow-up. Half of them continued for a longer period, half for less.

Approximately 73% of patients taking statins at the start of the study, eventually increasing to 81%, reported researchers.


Leave a comment

Send a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.